Latimozol FDC

OC135 (Latimozol FDC) is an ophthalmic fixed-dose combination (FDC) therapy developed by Nanomerics for the treatment of glaucoma and ocular hypertension. The formulation utilizes Nanomerics' proprietary Molecular Envelope Technology (MET), which employs chitosan-based nanoparticles (specifically N-palmitoyl-N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan, or GCPQ) to encapsulate and deliver poorly soluble active ingredients. OC135 contains latanoprost, a prostaglandin F2α analogue, and timolol, a non-selective beta-adrenergic antagonist. By combining these two mechanisms—increasing aqueous humor outflow via the uveoscleral pathway and decreasing aqueous humor secretion from the ciliary epithelium—the drug aims to provide superior intraocular pressure (IOP) reduction compared to monotherapies. The MET platform is designed to enhance ocular bioavailability and potentially reduce the frequency of administration or side effects associated with conventional eye drops. As of the latest pipeline updates, OC135 has completed Phase 1 clinical development.

Other names

Latimozol